Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC

Kohei Shigeta, Tai Hato, Yunching Chen, Dan G. Duda

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In hepatocellular carcinoma (HCC), chronic inflammation and vascular abnormalities often promote an environment characterized by hypoxia, immunosuppressive cell infiltration (M2-activated macrophages, T regulatory cells and myeloid-derived suppressor cells) and upregulation of immune checkpoints. These immunosuppressive cues lead to impaired effector CD8+ T lymphocyte infiltration and function, and ultimately to immune evasion. Reactivation of the immune response is critical to overcoming treatment resistance in HCC. Large clinical trials of anti-PD-1 blockade therapy are ongoing, and interim analyses showed promising responses in a subset of patients. The current challenge is to rationally combine anti-PD-1 antibodies with the existing drugs to substantially increase survival more broadly in HCC patients. Antiangiogenic multikinase inhibitors (sorafenib, regorafenib, lenvatinib) have shown efficacy in HCC. These drugs work in part by VEGF pathway inhibition in tumor endothelial cells, which can delay tumor growth. If the antivascular effects are too pronounced, treatment leads to increased hypoxia, inflammation, and fibrosis in the tumor tissues. These effects may affect anti-tumor immune response, which are critical for achieving durable treatment responses. Thus, successful implementation of combination therapies will require synergy between these interventions to reduce angiogenesis, modify vascular function, reverse the immunosuppressive environment and activate anti-tumor immunity in HCC.

Original languageEnglish
Title of host publicationImmunotherapy of Hepatocellular Carcinoma
PublisherSpringer International Publishing
Pages85-101
Number of pages17
ISBN (Electronic)9783319649580
ISBN (Print)9783319649573
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Immunosuppressive Agents
Neoplasms
Blood Vessels
Inflammation
Immune Evasion
Therapeutics
Cell Hypoxia
Regulatory T-Lymphocytes
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Cues
Immunity
Fibrosis
Up-Regulation
Endothelial Cells
Macrophages
Clinical Trials
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shigeta, K., Hato, T., Chen, Y., & Duda, D. G. (2017). Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC. In Immunotherapy of Hepatocellular Carcinoma (pp. 85-101). Springer International Publishing. https://doi.org/10.1007/978-3-319-64958-0_6

Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC. / Shigeta, Kohei; Hato, Tai; Chen, Yunching; Duda, Dan G.

Immunotherapy of Hepatocellular Carcinoma. Springer International Publishing, 2017. p. 85-101.

Research output: Chapter in Book/Report/Conference proceedingChapter

Shigeta, K, Hato, T, Chen, Y & Duda, DG 2017, Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC. in Immunotherapy of Hepatocellular Carcinoma. Springer International Publishing, pp. 85-101. https://doi.org/10.1007/978-3-319-64958-0_6
Shigeta K, Hato T, Chen Y, Duda DG. Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC. In Immunotherapy of Hepatocellular Carcinoma. Springer International Publishing. 2017. p. 85-101 https://doi.org/10.1007/978-3-319-64958-0_6
Shigeta, Kohei ; Hato, Tai ; Chen, Yunching ; Duda, Dan G. / Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC. Immunotherapy of Hepatocellular Carcinoma. Springer International Publishing, 2017. pp. 85-101
@inbook{0036b0a959a64dc8bd255e5b3ae2a64a,
title = "Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC",
abstract = "In hepatocellular carcinoma (HCC), chronic inflammation and vascular abnormalities often promote an environment characterized by hypoxia, immunosuppressive cell infiltration (M2-activated macrophages, T regulatory cells and myeloid-derived suppressor cells) and upregulation of immune checkpoints. These immunosuppressive cues lead to impaired effector CD8+ T lymphocyte infiltration and function, and ultimately to immune evasion. Reactivation of the immune response is critical to overcoming treatment resistance in HCC. Large clinical trials of anti-PD-1 blockade therapy are ongoing, and interim analyses showed promising responses in a subset of patients. The current challenge is to rationally combine anti-PD-1 antibodies with the existing drugs to substantially increase survival more broadly in HCC patients. Antiangiogenic multikinase inhibitors (sorafenib, regorafenib, lenvatinib) have shown efficacy in HCC. These drugs work in part by VEGF pathway inhibition in tumor endothelial cells, which can delay tumor growth. If the antivascular effects are too pronounced, treatment leads to increased hypoxia, inflammation, and fibrosis in the tumor tissues. These effects may affect anti-tumor immune response, which are critical for achieving durable treatment responses. Thus, successful implementation of combination therapies will require synergy between these interventions to reduce angiogenesis, modify vascular function, reverse the immunosuppressive environment and activate anti-tumor immunity in HCC.",
author = "Kohei Shigeta and Tai Hato and Yunching Chen and Duda, {Dan G.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-64958-0_6",
language = "English",
isbn = "9783319649573",
pages = "85--101",
booktitle = "Immunotherapy of Hepatocellular Carcinoma",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC

AU - Shigeta, Kohei

AU - Hato, Tai

AU - Chen, Yunching

AU - Duda, Dan G.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In hepatocellular carcinoma (HCC), chronic inflammation and vascular abnormalities often promote an environment characterized by hypoxia, immunosuppressive cell infiltration (M2-activated macrophages, T regulatory cells and myeloid-derived suppressor cells) and upregulation of immune checkpoints. These immunosuppressive cues lead to impaired effector CD8+ T lymphocyte infiltration and function, and ultimately to immune evasion. Reactivation of the immune response is critical to overcoming treatment resistance in HCC. Large clinical trials of anti-PD-1 blockade therapy are ongoing, and interim analyses showed promising responses in a subset of patients. The current challenge is to rationally combine anti-PD-1 antibodies with the existing drugs to substantially increase survival more broadly in HCC patients. Antiangiogenic multikinase inhibitors (sorafenib, regorafenib, lenvatinib) have shown efficacy in HCC. These drugs work in part by VEGF pathway inhibition in tumor endothelial cells, which can delay tumor growth. If the antivascular effects are too pronounced, treatment leads to increased hypoxia, inflammation, and fibrosis in the tumor tissues. These effects may affect anti-tumor immune response, which are critical for achieving durable treatment responses. Thus, successful implementation of combination therapies will require synergy between these interventions to reduce angiogenesis, modify vascular function, reverse the immunosuppressive environment and activate anti-tumor immunity in HCC.

AB - In hepatocellular carcinoma (HCC), chronic inflammation and vascular abnormalities often promote an environment characterized by hypoxia, immunosuppressive cell infiltration (M2-activated macrophages, T regulatory cells and myeloid-derived suppressor cells) and upregulation of immune checkpoints. These immunosuppressive cues lead to impaired effector CD8+ T lymphocyte infiltration and function, and ultimately to immune evasion. Reactivation of the immune response is critical to overcoming treatment resistance in HCC. Large clinical trials of anti-PD-1 blockade therapy are ongoing, and interim analyses showed promising responses in a subset of patients. The current challenge is to rationally combine anti-PD-1 antibodies with the existing drugs to substantially increase survival more broadly in HCC patients. Antiangiogenic multikinase inhibitors (sorafenib, regorafenib, lenvatinib) have shown efficacy in HCC. These drugs work in part by VEGF pathway inhibition in tumor endothelial cells, which can delay tumor growth. If the antivascular effects are too pronounced, treatment leads to increased hypoxia, inflammation, and fibrosis in the tumor tissues. These effects may affect anti-tumor immune response, which are critical for achieving durable treatment responses. Thus, successful implementation of combination therapies will require synergy between these interventions to reduce angiogenesis, modify vascular function, reverse the immunosuppressive environment and activate anti-tumor immunity in HCC.

UR - http://www.scopus.com/inward/record.url?scp=85042507034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042507034&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-64958-0_6

DO - 10.1007/978-3-319-64958-0_6

M3 - Chapter

AN - SCOPUS:85042507034

SN - 9783319649573

SP - 85

EP - 101

BT - Immunotherapy of Hepatocellular Carcinoma

PB - Springer International Publishing

ER -